Samsung announced that its application for electrocardiogram monitoring or otherwise ECG, has been given the green light by the US Food and Drug Administration (FDA). So far, South Korea has been the only country where the operation has been approved monitoring electrocardiogram of the company.
The ECG feature is available to users of the company's devices through the Samsung Health Monitor app when connected to a compatible smartphone Galaxy. ECG monitoring can also be used to monitor a user's heart rate but also to scan for any signs of abnormality or to detect signs of atrial fibrillation (AFib).
The company made the long-awaited debut of ECG in the US with its new Galaxy Watch 3 and Watch Active 2 smartwatches.
In 2017, the electronics company, along with AppleThe Fitbit and other companies participated in an FDA-led pilot project to accelerate the approval of healthcare-related applications and services as much as possible.
"We need to modernize our regulatory framework in such a way that it fits the type of innovation we are being asked to evaluate, and help promote useful technology, while ensuring that consumers have access to high quality." "Safe and effective digital devices for monitoring health," said then-FDA Commissioner Scott Gottlieb.
"These pilot participants will help the organization develop a better and more flexible approach to digital health technology, focusing on software programming rather than a single product."